Advancing Value-Based Healthcare in Asia
Using Decision Modelling to Inform Clinical and Public Policy Decision-Making
In this report we examine the shift in Asia, and globally, from supply-driven healthcare systems to value-based patient-centered healthcare systems. This report introduces the concept of value-based healthcare and illustrates how real-world data-driven decision modelling approaches can improve disease management and support value-based clinical and policy decision-making in Asia, offering applications in diabetes and stroke as case examples.
Explore the Institute
QuintilesIMS Institute App is now available for download on all iOS and Android devices:
Summary
Every healthcare system in Asia is struggling with rising costs and uneven quality of healthcare delivery. Over the past years, there has been a fundamental shift in expectations for healthcare systems: that they transform from supply-driven healthcare systems to value-based patient-centered healthcare systems organised around what patients need.
To address this shift successfully in Asia, and provide needed evidence to support value-based decision-making, real-world data-driven decision modelling approaches can be used to improve disease management. Application of decision modelling approaches to diabetes and stroke care using the IMS CORE Diabetes Model and the Duke-NUS Singapore Stroke Model, respectively, provide clear case examples of the value of these models to inform clinical and public health policy. In order for healthcare systems in Asia to fully realize the benefits of value-based healthcare (VBH) to optimize healthcare for the population and patients in a cost-effective manner, all stakeholders should join in the project of maximizing the role of health informatics and value-based decision models in guiding practice and policy.
The release of this report coincides with the launch of Asia Branch of the IMS Institutes for Healthcare Informatics. The IMS Institute for Healthcare Informatics is the first collaborative platform in Asia intended to foster technology-enabled, analytics-driven approaches to improve health outcomes in Asia, and bring together relevant stakeholders to shape clinical and public policy decision-making in order to optimize outcomes for patients.
Engage with Murray Aitken, executive director, QuintilesIMS Institute
Key Findings
Asia Faces a Number of Challenges and Opportunities in Implementing Value Based Healthcare
- Value-based healthcare (VBH) models come at a crucial point for Asia as the region’s diverse healthcare systems struggle with rising costs and uneven quality.
- The predominant use of paper-based patient records in the region, combined with a lack of technology and regulatory frameworks for electronic exchange, limit the use of digital health data to support VBH and evidence-based decision-making.
- For this reason, decision modelling will be a key tool in Asia to understand healthcare as a complex, interconnected system, and allow simulation of policy or clinical choices and their potential desirable and undesirable health and economic outcomes.
Decision Modelling Can Be Used to Simulate the Health Outcomes of Individual Patients or a Population Under a Variety of Scenarios
- Decision modelling enables healthcare options or interventions intended to add value to patients, to be developed and adjusted as needed in a simulated modelling environment to support clinical and public policy decision-making.
- A model that assesses ‘value for money’ can demonstrate an intervention’s impact on direct costs and patient outcomes, including quality of life, and how it alters key factors such as long-term disease complications and treatment-related effects such as adverse events.
The IMS CORE Diabetes Model (CDM) Predicts the Long-Term Health Outcomes and Costs Associated With the Management of Type I and Type II Diabetes
- Diabetes mellitus afflicts an estimated 75 million people in South East Asia alone and results in high direct and indirect costs.
- These costs are likely to increase in Asia, driving the need for successful value-based health models to clarify the value for money conferred by competing interventions.
- The CDM combines costs and health consequences associated with therapy choice and disease progression to provide robust estimates of cost-effectiveness.
- The CDM has been used extensively to evaluate the cost-effectiveness of new therapies for the treatment of diabetes, to inform reimbursement decisions, resource planning and clinical trial design, clarify public health issues, and identify optimal patient management strategies.
The Duke-NUS Singapore Stroke Model Tests Combinations of Interventions to Determine Their Expected System-Wide Impact in Singapore by 2030
- Two-thirds of the world’s deaths due to stroke are recorded in Asia where stroke cases are increasing and occurring at an earlier age than in the West
- The Duke-NUS Singapore Stroke Model is a dynamic population model to evaluate system-wide health and economic effects of improving the current level of stroke care through a variety of interventions ranging from a public campaign to encourage people with symptoms to seek care promptly, to more aggressive use of therapies such as thrombolytics, endovascular therapy, rehabilitation, and medications for secondary stroke prevention.
- The process of building this simulation model allowed various stakeholders to share their understanding of the current stroke management and exchange ideas for how to do better in stroke care.
Download Exhibits
In this report we examine the shift in Asia, and globally, from supply-driven healthcare systems to value-based patient-centered healthcare systems. This report introduces the concept of value-based healthcare and illustrates how real-world data-driven decision modelling approaches can improve disease management and support value-based clinical and policy decision-making in Asia, offering applications in diabetes and stroke as case examples.
The IMS Institute for Healthcare Informatics grants permission to use and reference this information, providing the IMS Institute report name and copyright information are clearly acknowledged. Exhibits may not be altered in any way.
Note: All third party trademarks contained herein are the property of their respective owners and their use herein is for informational purposes and does not imply sponsorship or endorsement of their products or services.
Please fill out the form below to request the Advancing Value-Based Healthcare in Asia report:
Required*